Most Read Articles
13 Oct 2017
Use of systemic antibiotics, in conjunction with performance of incision and drainage, in the management of paediatric acute skin and soft tissue infection (SSTI) appears to reduce Staphylococcus aureus colonization and the likelihood of infection recurrence, a prospective study has found.
12 Oct 2017
Retreatment with ledipasvir and sofosbuvir with add-on ribavirin appears to be effective and well tolerated in genotype 1 hepatitis C virus (HCV)-infected patients who have failed to respond to daclatasvir/asunaprevir combination therapy, according to a study.
6 days ago
Excessive intake of the mineral manganese can be toxic to the heart, according to a new study.

Daclatasvir plus asunaprevir effective, tolerable in older and younger genotype 1 HCV patients

04 Apr 2017

Virological response and tolerance with daclatasvir plus asunaprevir therapy appear to be similar between older and younger patients with chronic genotype 1 hepatitis C virus (HCV) infection, a study has shown.

A total of 170 genotype 1 HCV-infected patients in the younger cohort (<75 years) and 139 in the older cohort (≥75 years) received dual therapy with daclatasvir plus asunaprevir for 24 weeks. Efficacy and safety outcomes—virological response and adverse events, respectively—were analysed according to age. The Invader assay facilitated identification of pretreatment resistance-associated variants (RAVs) at NS5A-L31 and NS5A-Y93.

At treatment completion, the sustained virological response (SVR) rate did not differ significantly between the older and younger cohorts (97.1 vs 92.4 percent, respectively). Of note was that all very elderly patients in the cohort (≥85 years; n=19) completed the 24 weeks of treatment and achieved SVR.

On multivariate regression analysis, the absence of prior simeprevir treatment significantly and independently predicted SVR (odds ratio, 56.6; p<0.001).

At a low population frequency (<25 percent), the SVR rate was similar between patients with RAVs and those with no detectable RAVs. The frequency of adverse events was also similar between younger and older patients.

The present data provide evidence of the safety and efficacy of the daclatasvir and asunaprevir dual therapy for older patients with chronic genotype 1 HCV infection, with virological response and tolerance comparable to that of younger patients.

“Even though RAVs were detected, virological response similar to that for patients with no detectable RAVs may still be expected for patients with RAVs as long as the population frequency is low,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
13 Oct 2017
Use of systemic antibiotics, in conjunction with performance of incision and drainage, in the management of paediatric acute skin and soft tissue infection (SSTI) appears to reduce Staphylococcus aureus colonization and the likelihood of infection recurrence, a prospective study has found.
12 Oct 2017
Retreatment with ledipasvir and sofosbuvir with add-on ribavirin appears to be effective and well tolerated in genotype 1 hepatitis C virus (HCV)-infected patients who have failed to respond to daclatasvir/asunaprevir combination therapy, according to a study.
6 days ago
Excessive intake of the mineral manganese can be toxic to the heart, according to a new study.